Literature DB >> 7671966

The role of polyols in the pathophysiology of hypergalactosemia.

G T Berry1.   

Abstract

Cellular accumulation of galactitol has been suggested to cause the apparent dietary-independent, long-term complications in classic galactosemia. Experimental animals rendered hypergalactosemic by galactose feeding accumulate tissue galactitol, as well as millimolar quantities of galactose, and manifest biochemical, physiological and pathological abnormalities which are generally eliminated or curtailed by the concomitant administration of an aldose reductase inhibitor. This includes reduced cellular content of the cyclic polyol, myo-inositol, which like galactitol may function as an alternate intracellular osmolyte. However, the abnormalities detected in experimental galactosemic animals are more compatible with findings in experimental diabetes mellitus than in human galactosemia. Because patients with galactokinase deficiency fail to manifest the CNS and ovarian complications which characterize classic galactosemia, yet during long-term lactose restriction excrete comparable urinary quantities of galactitol, this polyol alone is not likely to play an important role during postnatal life in the pathogenesis of long-term complications. Notwithstanding, a role for either galactitol or myo-inositol in an intrauterine toxicity cannot be dismissed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671966     DOI: 10.1007/bf02143805

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  119 in total

Review 1.  Metabolism and function of myo-inositol and inositol phospholipids.

Authors:  B J Holub
Journal:  Annu Rev Nutr       Date:  1986       Impact factor: 11.848

2.  Purification, structure, and catalytic properties of L-myo-inositol-1-phosphate synthase from rat testis.

Authors:  T Maeda; F Eisenberg
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

3.  Edema and increased endoneurial sodium in galactose neuropathy. Reversal with an aldose reductase inhibitor.

Authors:  A P Mizisin; H C Powell; R R Myers
Journal:  J Neurol Sci       Date:  1986-06       Impact factor: 3.181

4.  Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.

Authors:  R L Engerman; T S Kern
Journal:  Diabetes       Date:  1993-06       Impact factor: 9.461

5.  The effect of dietary fruits and vegetables on urinary galactitol excretion in galactose-1-phosphate uridyltransferase deficiency.

Authors:  G T Berry; M Palmieri; K C Gross; P B Acosta; J A Henstenburg; A Mazur; R Reynolds; S Segal
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.

Authors:  R L Engerman; T S Kern; M E Larson
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

7.  Galactose-induced retinal capillary basement membrane thickening: prevention by Sorbinil.

Authors:  R N Frank; R J Keirn; A Kennedy; K W Frank
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-11       Impact factor: 4.799

8.  Ophthalmic findings in classical galactosaemia--prospective study.

Authors:  B Beigi; M O'Keefe; R Bowell; E Naughten; N Badawi; B Lanigan
Journal:  Br J Ophthalmol       Date:  1993-03       Impact factor: 4.638

9.  Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.

Authors:  M Datiles; H Fukui; T Kuwabara; J H Kinoshita
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-02       Impact factor: 4.799

10.  Schwann cell injury is attenuated by aldose reductase inhibition in galactose intoxication.

Authors:  A P Mizisin; H C Powell
Journal:  J Neuropathol Exp Neurol       Date:  1993-01       Impact factor: 3.685

View more
  15 in total

Review 1.  Galactosaemia: pathogenesis and treatment.

Authors:  J B Holton
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

2.  Komrower Lecture. Galactosaemia today: the enigma and the challenge.

Authors:  S Segal
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

3.  Importance of sustained high glucose condition in the development of diabetic osteopenia: possible involvement of the polyol pathway.

Authors:  M Inaba; Y Nishizawa; A Shioi; H Morii
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

4.  The male reproductive system in classic galactosemia: cryptorchidism and low semen volume.

Authors:  Cynthia S Gubbels; Corrine K Welt; John C M Dumoulin; Simon G F Robben; Catherine M Gordon; Gerard A J Dunselman; M Estela Rubio-Gozalbo; Gerard T Berry
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

5.  Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia.

Authors:  Bijina Balakrishnan; Ding An; Vi Nguyen; Christine DeAntonis; Paolo G V Martini; Kent Lai
Journal:  Mol Ther       Date:  2019-09-19       Impact factor: 11.454

Review 6.  Is prenatal myo-inositol deficiency a mechanism of CNS injury in galactosemia?

Authors:  Gerard T Berry
Journal:  J Inherit Metab Dis       Date:  2011-01-19       Impact factor: 4.982

7.  Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.

Authors:  William T Regenold; Pornima Phatak; Michael J Makley; Roger D Stone; Mitchel A Kling
Journal:  J Neurol Sci       Date:  2008-09-09       Impact factor: 3.181

Review 8.  Galactose toxicity in animals.

Authors:  Kent Lai; Louis J Elsas; Klaas J Wierenga
Journal:  IUBMB Life       Date:  2009-11       Impact factor: 3.885

9.  ARHI: A new target of galactose toxicity in Classic Galactosemia.

Authors:  K Lai; M Tang; X Yin; H Klapper; K Wierenga; Lj Elsas
Journal:  Biosci Hypotheses       Date:  2008

10.  Galactitol in galactosemia.

Authors:  C Jakobs; S Schweitzer; B Dorland
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.